2-(2-((2-aminoethoxy)ethoxy)ethoxy)ethanol hydrochloride | 1247064-67-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-(2-((2-aminoethoxy)ethoxy)ethoxy)ethanol hydrochloride
• 英文别名: 2-{2-[2-(2-Aminoethoxy)ethoxy]ethoxy}ethan-1-ol hydrochloride；2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]ethanol;hydrochloride
• CAS: 1247064-67-0
• 化学式: C₈H₁₉NO₄*ClH
• 分子量: 229.704
• InChiKey: VIPVOBPGUXMNCY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.59
• 重原子数：
  14
• 可旋转键数：
  10
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  73.9
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-(2-((2-aminoethoxy)ethoxy)ethoxy)ethanol hydrochloride 在 N-羟基-7-氮杂苯并三氮唑 、 phospholipase D from Streptomyces sp 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 氯仿 、 叔丁醇 为溶剂， 反应 17.0h， 生成
  参考文献：
  名称：

  Ligand–Phospholipid Conjugation: A Versatile Strategy for Developing Long-Acting Ligands That Bind to Membrane Proteins by Restricting the Subcellular Localization of the Ligand

  摘要：

  We hypothesized that if drug localization can be restricted to a particular subcellular domain where their target proteins reside, the drugs could bind to their target proteins without being metabolized and/or excreted, which would significantly extend the half-life of the corresponding drug target complex. Thus, we designed ligand phospholipid conjugates in which the ligand is conjugated with a phospholipid through a polyethylene glycol linker to restrict the subcellular localization of the ligand in the vicinity of the lipid bilayer. Here, we present the design, synthesis, pharmacological activity, and binding mode analysis of ligand phospholipid conjugates with muscarinic acetylcholine receptors as the target proteins. These results demonstrate that ligand phospholipid conjugation can be a versatile strategy for developing long-acting ligands that bind to membrane proteins in drug discovery.

  DOI：

  10.1021/acs.jmedchem.8b00041
• 作为产物：
  描述：

  11-叠氮基-3,6,9-三氧杂十一醇 在 盐酸 、 palladium 10% on activated carbon 、 氢气 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 乙酸乙酯 为溶剂， 20.0 ℃ 、103.42 kPa 条件下， 反应 19.0h， 生成 2-(2-((2-aminoethoxy)ethoxy)ethoxy)ethanol hydrochloride
  参考文献：
  名称：

  IRAK DEGRADERS AND USES THEREOF

  摘要：

  本发明提供了化合物、其组合物以及使用这些化合物的方法。

  公开号：

  US20190192668A1

文献信息

• Tetracyclic Anthraquinone Derivatives
  申请人：Tianjin Hemay Bio-Tech Co., Ltd

  公开号：US20150166595A1

  公开（公告）日：2015-06-18

  Disclosed are a compound represented by formula (I) and a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , W, n are defined as in the present application.

  公开了一种由式（I）表示的化合物及其药用可接受的盐，其中R1、R2、R3、R4、R5、W、n的定义如本申请中所述。
• Highly functionalized diaminocyclopentanes: A new route to potent and selective inhibitors of human O-GlcNAcase
  作者：Patrick Weber、Zuzana Mészáros、Pavla Bojarová、Manuel Ebner、Roland Fischer、Vladimír Křen、Natalia Kulik、Philipp Müller、Miluše Vlachová、Kristýna Slámová、Arnold E. Stütz、Martin Thonhofer、Ana Torvisco、Tanja M. Wrodnigg、Andreas Wolfsgruber

  DOI：10.1016/j.bioorg.2023.106819

  日期：2023.11

  A new class of compounds inhibiting de-O-glycosylation of proteins has been identified. Highly substituted diaminocyclopentanes are impressively selective reversible non-transition state O-β-N-acetyl-d-glucosaminidase (O-GlcNAcase) inhibitors. The ease of preparative access and remarkable biological activities provide highly viable leads for the development of anti-tau-phosphorylation agents with a

  已经鉴定出一类新的抑制蛋白质去-O-糖基化的化合物。高度取代的二氨基环戊烷是令人印象深刻的选择性可逆非过渡态O -β- N -乙酰基-d-氨基葡萄糖苷酶 ( O -GlcNAcase) 抑制剂。易于制备和显着的生物活性为抗 tau 磷酸化药物的开发提供了高度可行的线索，以期最终改善阿尔茨海默病。
• Tetracyclic anthraquinone derivatives
  申请人：TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD.

  公开号：US10294260B2

  公开（公告）日：2019-05-21

  Disclosed are a compound represented by formula (I) and a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, W, n are defined as in the present application. Also disclosed is a method for treating cancer, comprising administering to a subject in need thereof a therapeutically effective amount of the compound represented by formula (I) or a pharmaceutically acceptable salt thereof. The compound and a salt thereof according to the present application possess good anticancer and/or antitumor activity, and good water solubility and stability, as well as good tolerance in animal bodies. Also disclosed is a process for preparing a compound represented by formula (I) of the present application.

  公开了一种由式 (I) 代表的化合物及其药学上可接受的盐、 其中 R1、R2、R3、R4、R5、W、n 的定义与本申请相同。还公开了一种治疗癌症的方法，包括向有需要的受试者施用治疗有效量的式 (I) 所代表的化合物或其药学上可接受的盐。根据本申请的化合物及其盐具有良好的抗癌和/或抗肿瘤活性、良好的水溶性和稳定性，以及在动物体内良好的耐受性。本申请还公开了一种制备式（I）所代表的化合物的工艺。
• TETRACYCLIC ANTHRAQUINONE DERIVATIVES
  申请人：Tianjin Hemay Bio-Tech Co., Ltd.

  公开号：EP2824108B1

  公开（公告）日：2017-04-19
• US9670242B2
  申请人：——

  公开号：US9670242B2

  公开（公告）日：2017-06-06